Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-021760
Filing Date
2021-11-04
Accepted
2021-11-04 16:09:13
Documents
87
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20210930.htm   iXBRL 10-Q 2335591
2 EX-10.1 exhibit101-formofperforman.htm EX-10.1 43347
3 EX-10.2 exhibit102-formofpsuagreem.htm EX-10.2 32056
4 EX-10.3 exhibit103-akebiaxformofca.htm EX-10.3 18398
5 EX-31.1 exhibit311-q320211.htm EX-31.1 11369
6 EX-31.2 exhibit312-q320211.htm EX-31.2 11409
7 EX-32.1 exhibit321-q320211.htm EX-32.1 9281
  Complete submission text file 0001628280-21-021760.txt   9842984

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20210930.xsd EX-101.SCH 86485
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20210930_cal.xml EX-101.CAL 98119
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20210930_def.xml EX-101.DEF 378543
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20210930_lab.xml EX-101.LAB 774076
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20210930_pre.xml EX-101.PRE 548892
13 EXTRACTED XBRL INSTANCE DOCUMENT akba-20210930_htm.xml XML 1508386
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 211379986
SIC: 2834 Pharmaceutical Preparations